

Special Issue

Coronavirus Disease (COVID-19) and Its Impact on Patients with Cancer

Message from the Guest Editor

Coronavirus disease (COVID-19) became a global pandemic in 2020. This continues to impact upon patients with cancer. The ongoing pandemic, with its multiple variants and waves of disease, has resulted in missed or delayed cancer diagnosis, alterations to standard treatment and risk of severe outcomes including increased morbidity or death following COVID-19. Patients with cancer appear to be at greater risk compared to those without cancer following infection with SARS-CoV-2. Vaccination offers protection; however, this protection is reduced for those who are immunocompromised such as those with cancer. The global oncology community responded to the COVID-19 pandemic with many COVID-19 and cancer registries and studies. These studies have identified potential risk factors for worse outcomes, including advanced or metastatic disease, hematological malignancies, and potentially certain classes of systemic anticancer treatments. We hope that this Special Issue will collect and highlight the evidence needed to help shape long-term management of patients with cancer in a world where COVID-19 remains a risk. We look forward to your contributions.

Guest Editor

Dr. Alvin Lee
The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK

Deadline for manuscript submissions

closed (28 April 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/106295

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)